Médecine

Paramédical

Autres domaines


S'abonner

Poor prognosis for thin ulcerated melanomas and implications for a more aggressive approach to treatment - 16/05/19

Doi : 10.1016/j.jaad.2019.01.009 
Makenzie L. Hawkins, MSPH a, Matthew J. Rioth, MD a, b, Megan M. Eguchi, MPH a, Myles Cockburn, PhD a, c, d, e,
a University of Colorado Cancer Center, University of Colorado, Aurora, Colorado 
b Department of Medicine-Biomedical Informatics and Personalized Medicine, School of Medicine, University of Colorado, Aurora, Colorado 
c Department of Dermatology, School of Medicine, University of Colorado, Aurora, Colorado 
d Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California 
e Department of Dermatology, Keck School of Medicine of the University of Southern California, Los Angeles, California 

Correspondence to: Myles Cockburn, PhD, 13001 E 17th Place, Campus Box F434, Aurora, CO 80045.13001 E 17th Place, Campus Box F434AuroraCO80045

Abstract

Background

Clinical guidelines for the treatment of melanoma are based largely on the behavior of thicker tumors. As a result, little is known about survival differences among patients with thinner tumors.

Objective

To investigate the variability in survival for American Joint Committee on Cancer stage T1 thin melanoma tumors, defined as tumors less than 1 mm thick at diagnosis.

Methods

This population-based series included 43,008 non-Hispanic whites in whom cutaneous melanoma was diagnosed between 2004 and 2013 from the California Cancer Registry. Survival outcomes were estimated using the Kaplan-Meier method. Cox proportional hazard models were used to estimate risk of death.

Results

Survival for patients with thin ulcerated tumors was comparable to that for patients with stage II tumors, who are currently treated more aggressively. At 12 months, patients with thin ulcerated tumors had approximately 6% lower survival (92.5% [95% confidence interval (CI), 90.6%-93.9%]) compared with patients with thin nonulcerated tumors (98.2% [95% CI, 98.0%-98.3%]). At 24 months, this survival difference increased (85.2% [95% CI, 82.8%-87.4%] vs 96.1% [95% CI, 95.8-96.3%] for those with thin ulcerated and thin nonulcerated tumors, respectively) and a greater than 15% survival difference was seen at 60 months.

Limitations

Previous reports of cancer registry data have noted some evidence of miscoding of thin tumors.

Conclusion

The poorer survival in patients with ulcerated tumors less than 1 mm thick implies the need for additional studies to determine potential benefits of more aggressive treatment.

Le texte complet de cet article est disponible en PDF.

Key words : melanoma, staging, survival, tumor thickness

Abbreviations used : CI, SEER, SES, SLN, SLNB


Plan


 Funding sources: Supported by grant R01CA158407 from the National Cancer Institute and the National Institute of Child Health and Human Development. The collection of cancer incidence data used in this study was supported by the California Department of Public Health pursuant to California Health and Safety Code Section 103885; the Centers for Disease Control and Prevention's National Program of Cancer Registries, under cooperative agreement 5NU58DP003862-04/DP003862; and the National Cancer Institute's Surveillance, Epidemiology and End Results Program under contract HHSN2 61201000140C awarded to the Cancer Prevention Institute of California, contract HHSN261201000035C awarded to the University of Southern California, and contract HHSN261201000034C awarded to the Public Health Institute. Supported in part by the Population Health Shared Resource of the University of Colorado Cancer Center (P30CA046934).
 Conflicts of interest: None disclosed.
 The ideas and opinions expressed herein are those of the author(s) and do not necessarily reflect the opinions of the State of California, Department of Public Health, the National Cancer Institute, and the Centers for Disease Control and Prevention or their contractors and subcontractors.
 Reprints not available from the authors.


© 2019  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 80 - N° 6

P. 1640-1649 - juin 2019 Retour au numéro
Article précédent Article précédent
  • Prevalence of clinically significant incidental findings by whole-body fludeoxyglucose F 18 positron emission tomography/computed tomography scanning in moderate-to-severe psoriasis patients participating in clinical trials
  • Marilyn T. Wan, Drew A. Torigian, Abass Alavi, Judith Alvarez, Zelma C. Chiesa Fuxench, Megan H. Noe, Maryte Papadopoulos, Daniel B. Shin, Junko Takeshita, Thomas J. Werner, Nehal N. Mehta, Joel M. Gelfand
| Article suivant Article suivant
  • Patient-reported outcomes are important elements of psoriasis treatment decision making: A discrete choice experiment survey of dermatologists in the United States
  • Steven R. Feldman, Stephane A. Regnier, Alexandra Chirilov, Felix Hey, Isabelle Gilloteau, David Cella

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.